Fennec Pharmaceuticals Inc. (FENC)
- Previous Close
6.48 - Open
6.51 - Bid 4.63 x 200
- Ask 8.11 x 200
- Day's Range
6.30 - 6.55 - 52 Week Range
3.96 - 7.64 - Volume
56,597 - Avg. Volume
83,160 - Market Cap (intraday)
174.67M - Beta (5Y Monthly) 0.32
- PE Ratio (TTM)
-- - EPS (TTM)
-0.02 - Earnings Date Aug 11, 2025 - Aug 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.80
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
fennecpharma.comRecent News: FENC
View More
Performance Overview: FENC
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FENC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FENC
View MoreValuation Measures
Market Cap
171.49M
Enterprise Value
164.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.63
Price/Book (mrq)
--
Enterprise Value/Revenue
3.45
Enterprise Value/EBITDA
34.22
Financial Highlights
Profitability and Income Statement
Profit Margin
-46.71%
Return on Assets (ttm)
-12.96%
Return on Equity (ttm)
--
Revenue (ttm)
30.91M
Net Income Avi to Common (ttm)
-14.44M
Diluted EPS (ttm)
-0.02
Balance Sheet and Cash Flow
Total Cash (mrq)
22.68M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--